Tirzepatide vs Semaglutide: Research Compared

Quick Answer

Tirzepatide and semaglutide are two distinct peptide molecules that are frequently compared in the scientific literature. The simplest way the literature distinguishes them is by receptor target. Semaglutide is described as a single incretin pathway agent, a glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide is described as a dual incretin agent, acting on both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor within a single molecule.

Both are prescription medicines in Australia. Tirzepatide is registered on the Australian Register of Therapeutic Goods (ARTG) under the brand Mounjaro (Eli Lilly), and semaglutide is registered under the brands Ozempic and Wegovy (Novo Nordisk). Both are Schedule 4 (prescription only) substances in Australia. This guide compares how they are studied in the literature and does not provide any dosing, protocol or personal recommendation.

Mechanism of Action in the Literature

The incretin system refers to gut-derived hormones that influence insulin and glucagon release in a glucose-dependent manner. GLP-1 and GIP are the two principal incretin hormones studied in this context. Semaglutide is characterised in the literature as a selective GLP-1 receptor agonist, meaning it engages the GLP-1 receptor pathway alone.

Tirzepatide is characterised as a single molecule that activates both the GIP receptor and the GLP-1 receptor. For this reason it is often described in the literature as a dual GIP and GLP-1 receptor agonist, and some papers describe its receptor engagement as imbalanced or biased between the two pathways. This dual-receptor framing is the central mechanistic difference researchers cite when contrasting the two compounds.

How the literature frames each molecule

• Semaglutide: single-pathway GLP-1 receptor agonist (Novo Nordisk).
• Tirzepatide: dual GIP and GLP-1 receptor agonist in one molecule (Eli Lilly).
• Both act on incretin receptors that signal in a glucose-dependent manner.
• Both are long-acting peptides engineered for extended circulation.

Pharmacokinetics as a Factual Note

As a pharmacokinetic fact reported in the literature, both compounds are long-acting and are described as once-weekly subcutaneous agents in their registered injectable forms. Semaglutide is reported to have a half-life of roughly one week, which is the property that supports a weekly administration schedule in the trial literature. Tirzepatide is likewise described as a once-weekly subcutaneous molecule in its clinical programmes.

These are descriptions of molecular properties as reported in published studies and product information. They are not instructions, schedules or protocols, and nothing here should be read as guidance for use in any living subject.

Clinical Trial Programmes

Each compound has its own named clinical trial programme, and these names recur throughout the comparative literature. Understanding the programme names helps when reading source papers.

Tirzepatide programmes

• SURPASS: the phase 3 programme studying tirzepatide in the type 2 diabetes setting.
• SURMOUNT: the phase 3 programme studying tirzepatide in the context of weight and obesity research.

Semaglutide programmes

• SUSTAIN: the programme studying semaglutide in type 2 diabetes, including the SUSTAIN-6 cardiovascular outcomes study.
• STEP: the programme studying semaglutide at higher weekly doses in the overweight and obesity research setting.
• SELECT: a large cardiovascular outcomes study of semaglutide in adults with established cardiovascular disease.

These programmes differ in their enrolled populations, dose ranges and endpoints, so cross-programme comparisons should be read with care. The literature treats them as separate bodies of evidence rather than directly interchangeable.

The Head to Head Trial (SURMOUNT-5)

SURMOUNT-5 is reported as the first published head-to-head randomised comparison of tirzepatide and semaglutide. It is described as a phase 3b, open-label, randomised controlled trial in adults living with obesity but without diabetes. The literature notes the open-label design was used because the two agents differ in injection volume, device format and titration interval, which makes blinding difficult.

According to the published report, participants were randomised one to one to the maximum tolerated dose of each agent administered subcutaneously once weekly across a 72-week period, with randomisation stratified by baseline BMI category and geographic region. The primary endpoint was described as the percentage change in body weight from baseline to week 72, with secondary endpoints including change in waist circumference and the proportion of participants reaching defined weight-reduction thresholds.

When reading any head-to-head result, the literature stresses the importance of the specific population studied, the doses compared and the defined endpoints, rather than extrapolating a single figure to any person or setting.

Regulatory Status in Australia

Both tirzepatide and semaglutide are approved prescription medicines in Australia. The Therapeutic Goods Administration (TGA) published an Australian Public Assessment Report for Mounjaro (tirzepatide) dated November 2023, and the compound is registered on the ARTG. Semaglutide is registered on the ARTG under the brands Ozempic and Wegovy.

Both substances are classified as Schedule 4 (Prescription Only Medicine) in Australia, meaning a registered medicine containing them can only be supplied on prescription through the regulated pharmaceutical supply chain. Brand-name registration applies to specific manufactured products and does not extend to research-grade material supplied for laboratory use.

How to Read Comparisons Responsibly

Comparative articles often reduce two large bodies of evidence to a single headline number. The research literature is more cautious. A fair comparison considers the receptor mechanism, the differing trial populations, the dose ranges tested, the defined endpoints and the follow-up duration before drawing any conclusion.

Questions to keep in mind when reading sources

• What population was enrolled, and did it include people with or without diabetes?
• Which doses were compared, and were they at maximum tolerated levels?
• What was the defined primary endpoint and over what time period?
• Was the study blinded or open-label, and why?
• Is the result from a direct head-to-head trial or a cross-trial comparison?

Treating these as open research questions, rather than as settled advice, keeps the comparison accurate and avoids over-reading any single statistic.

Frequently asked questions